MX2010002196A - Composicion radiofarmaceutica. - Google Patents

Composicion radiofarmaceutica.

Info

Publication number
MX2010002196A
MX2010002196A MX2010002196A MX2010002196A MX2010002196A MX 2010002196 A MX2010002196 A MX 2010002196A MX 2010002196 A MX2010002196 A MX 2010002196A MX 2010002196 A MX2010002196 A MX 2010002196A MX 2010002196 A MX2010002196 A MX 2010002196A
Authority
MX
Mexico
Prior art keywords
radiopharmaceutical composition
radiopharmaceutical
composition
radiopharmaceuticals
polysorbate
Prior art date
Application number
MX2010002196A
Other languages
English (en)
Inventor
Sarah Elizabeth Paterson
Line Roed
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MX2010002196A publication Critical patent/MX2010002196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a radiofarmacéuticos y en particular a una composición radiofarmacéutica que comprende un compuesto de Fórmula (I): y polisorbato como un excipiente. La composición radiofarmacéutica de la invención reduce los problemas encontrados con composiciones de técnica anterior comprendiendo la misma clase de compuestos. También es provisto por la invención un método para la preparación de la composición radiofarmacéutica de la invención así como usos particulares de la composición radiofarmacéutica. (Ver fórmula I).
MX2010002196A 2007-08-30 2008-08-28 Composicion radiofarmaceutica. MX2010002196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96890407P 2007-08-30 2007-08-30
PCT/EP2008/061275 WO2009027452A2 (en) 2007-08-30 2008-08-28 Radiopharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2010002196A true MX2010002196A (es) 2010-03-18

Family

ID=40029249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002196A MX2010002196A (es) 2007-08-30 2008-08-28 Composicion radiofarmaceutica.

Country Status (21)

Country Link
US (1) US8916131B2 (es)
EP (1) EP2182988B1 (es)
JP (1) JP5367708B2 (es)
KR (1) KR101571572B1 (es)
CN (1) CN101790387B (es)
AU (1) AU2008292201B2 (es)
BR (1) BRPI0815129B8 (es)
CA (1) CA2694084C (es)
DK (1) DK2182988T3 (es)
ES (1) ES2464715T3 (es)
HK (1) HK1146710A1 (es)
HU (1) HUS1500007I1 (es)
IL (1) IL203316A (es)
MX (1) MX2010002196A (es)
NO (1) NO2015006I1 (es)
NZ (1) NZ583616A (es)
PL (1) PL2182988T3 (es)
PT (1) PT2182988E (es)
RU (1) RU2475267C2 (es)
WO (1) WO2009027452A2 (es)
ZA (1) ZA201000718B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044410A2 (en) 2009-10-08 2011-04-14 Ge Healthcare Limited Solid phase extraction purification method
CN109125745B (zh) 2012-04-10 2022-07-26 蓝瑟斯医学影像公司 放射性药物合成方法
CN106999603B (zh) 2014-12-04 2022-05-27 通用电气健康护理有限公司 从放射性药物中除去乙醛的方法
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法
JP6955347B2 (ja) 2017-02-28 2021-10-27 日本メジフィジックス株式会社 フルテメタモルの製造方法
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
US20230110526A1 (en) * 2020-03-27 2023-04-13 Jubilant Pharma Holdings Inc. Radiopharmaceutical dispensing systems
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335095A (en) * 1979-03-21 1982-06-15 The Radiochemical Centre Limited Indium-111 oxine complex composition
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
AU8670201A (en) * 2000-08-24 2002-03-04 Univ Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US20050123477A1 (en) * 2002-02-13 2005-06-09 Ian Wilson Benzothiazole derivatives for in vivo imaging of amloid plaques
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20050043523A1 (en) * 2003-08-22 2005-02-24 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
RU2007104106A (ru) * 2004-07-02 2008-08-10 Юнивесити оф Питсбэг (US) Способ выявления пациента, находящегося в продромальной стадии заболевания, ассоциированного с отложением амилоида (варианты), способ диагностики вышеуказанной продромальной стадии и тиофлавиновые производные, являющиеся компонентами диагностикумов вышеуказанной продромальной стадии (варианты)
CN101137397A (zh) * 2004-07-02 2008-03-05 匹兹堡大学高等教育联邦体系 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物
AU2006261917A1 (en) * 2005-06-24 2007-01-04 The Trustees Of The University Of Pennsylvania Radiolabeled-pegylation of ligands for use as imaging agents
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
WO2007064773A2 (en) 2005-12-01 2007-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders

Also Published As

Publication number Publication date
NO2015006I2 (es) 2015-02-18
CN101790387A (zh) 2010-07-28
PL2182988T3 (pl) 2015-02-27
BRPI0815129B8 (pt) 2021-05-25
BRPI0815129A2 (pt) 2015-02-03
CA2694084C (en) 2015-07-07
EP2182988B1 (en) 2014-04-16
US20110008254A1 (en) 2011-01-13
ES2464715T3 (es) 2014-06-03
NO2015006I1 (no) 2015-03-02
PT2182988E (pt) 2014-05-16
HUS1500007I1 (hu) 2021-05-07
HK1146710A1 (en) 2011-07-08
BRPI0815129B1 (pt) 2021-01-12
NZ583616A (en) 2012-06-29
CA2694084A1 (en) 2009-03-05
RU2475267C2 (ru) 2013-02-20
RU2010101935A (ru) 2011-10-10
CN101790387B (zh) 2013-03-20
AU2008292201B2 (en) 2014-09-04
IL203316A (en) 2015-02-26
ZA201000718B (en) 2010-10-27
KR20100055440A (ko) 2010-05-26
AU2008292201A1 (en) 2009-03-05
KR101571572B1 (ko) 2015-11-24
US8916131B2 (en) 2014-12-23
WO2009027452A2 (en) 2009-03-05
DK2182988T3 (da) 2014-05-26
JP5367708B2 (ja) 2013-12-11
JP2010536931A (ja) 2010-12-02
WO2009027452A3 (en) 2009-09-03
EP2182988A2 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
HK1146710A1 (en) Radiopharmaceutical composition
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2010004493A (es) Compuestos de tropano.
MX2010005824A (es) Derivados de aminotiazol.
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
MX2009005048A (es) Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
TW200730511A (en) Chroman compounds
MY150082A (en) Trans-clomiphene for metabolic syndrome
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
IN2012DN03337A (es)
MX2009010567A (es) Derivados de imidazolidinona.
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2010009860A (es) Sintesis total de salinosporamida a y sus analogos.
WO2012178129A3 (en) Quaternary heteroatom containing compounds
NO20085317L (no) Imidazoazepinonforbindelser
TW200730510A (en) Chroman compounds
ME00961B (me) Derivati-7 alkinil-1,8-naftiridoni, njihova priprema i njihova primjena u liječenju
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
PH12015502684B1 (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
MX2009008028A (es) Agentes antiparasitarios.
WO2011088474A3 (en) Sulindac and sulindac derivatives and their uses related to infection

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration